Growth hormone fragment
AOD-9604
AOD-9604 is a peptide made from amino acids 177 to 191 of human growth hormone plus one tyrosine. Its 24-week obesity trial in 502 adults did not reach its weight-loss endpoint.1
AOD-9604 after one dose: 50% at ~30 min, 25% at 60 min, 12.5% at 90 min.
Drawn from the half-life in the app's model, ~30 min. The model's figures
- Compound
- AOD-9604
- Symbol
- AOD
- Family
- Growth hormone peptides
- Parts
- 13
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
AOD-9604 is a 16-amino-acid peptide made from amino acids 177 to 191 of human growth hormone (hGH) with an extra tyrosine at one end.2,1 Some sources name the same fragment hGH 176-191.3
Metabolic Pharmaceuticals in Australia developed it as an obesity drug. On 21 February 2007 the company announced that its phase 2b results did not support commercial viability and that development for obesity was terminated.1
FDA states that neither the free base nor the acetate is a component of an FDA-approved drug, and a 2026 review in Frontiers in Endocrinology states that it is “not approved by major regulatory agencies for any indication”.1,3
Searching PubMed on 16 November 2026 for AOD9604 or AOD-9604 in the title or summary text returned 22 records. Limiting that search, with both spellings, to the publication types randomized controlled trial or clinical trial returned 0 records. Searching ClinicalTrials.gov the same day for AOD9604 and for AOD-9604 returned 0 records for each. The 2013 paper by Stier and colleagues, which summarises the six human trials, was not among the 22 PubMed records.
How it works
What the cell and animal studies reported
In a cell test, AOD-9604 did not compete with hGH for the hGH receptor and did not induce cell proliferation, unlike hGH, according to Heffernan and colleagues (Monash University) in the International Journal of Obesity, 2001.4
In the same paper, obese ob/ob mice given AOD-9604 or hGH for 14 days by mini-osmotic pump gained less body weight, with increased fat oxidation and plasma glycerol, an index of lipolysis. Unlike hGH, AOD-9604 did not induce hyperglycaemia or reduce insulin secretion in those mice.4
A second mouse paper from the same Monash group (Heffernan and colleagues, Endocrinology, 2001) reported that 14 days of intraperitoneal AOD-9604 reduced body weight and body fat in obese mice and raised beta-3 adrenergic receptor RNA. In beta-3 receptor knock-out mice, long-term treatment “failed to produce the change in body weight and increase in lipolysis” seen in wild-type mice, although in an acute experiment AOD-9604 increased energy expenditure and fat oxidation in the knock-out mice; the authors concluded that the lipolytic actions “are not mediated directly through the beta(3)-AR”.5
In obese Zucker rats, 500 micrograms/kg by mouth daily for 19 days gave a body weight gain of 15.8 ± 0.6 g against 35.6 ± 0.8 g in controls, and euglycemic clamp testing showed no adverse effect on insulin sensitivity (Ng and colleagues, Hormone Research, 2000).6
FDA's 2024 evaluation of these studies states that none assessed dose-response relationships and that “the molecular targets for AOD-9604 have not been identified and its mechanisms of action remain unknown”.1
In a collagenase-induced knee osteoarthritis model in 32 rabbits, weekly intra-articular injections of 0.25 mg AOD-9604 gave lower cartilage degeneration scores than saline, and AOD-9604 with hyaluronic acid scored lower than either alone (Kwon and Park, Annals of Clinical and Laboratory Science, 2015).7 A 2026 review states that claims about osteoarthritis and joint repair are “grounded mainly in animal work”, “with a lack of convincing human clinical trial evidence in these indications”.3
Pharmacokinetics
The app's figures are a half-life of about 30 minutes, a time to peak of about 15 minutes and a bioavailability of 95% by subcutaneous injection. The sources below give different figures, all from animals or laboratory tests.
FDA's 2024 evaluation states: “FDA did not identify clinical studies in humans assessing pharmacokinetics or pharmacodynamics of AOD-9604 via any ROA.” A 2026 review lists the half-life as “not reported in human trials”.1,3
| Measure | App's figure | Source's figure | Reference |
|---|---|---|---|
| Half-life | About 30 minutes | About 3 minutes after an intravenous bolus of 400 µg/kg in pigs; 4 minutes in rat blood in a laboratory test, fully hydrolyzed in 56 minutes | Moré and Kenley, 2014, as summarised by FDA, 20241 |
| Time to peak | About 15 minutes | About 60 minutes after an oral dose of 2 mg/kg in pigs; tissue radioactivity peaked about 30 minutes after oral gavage in rats | Moré and Kenley, 2014, as summarised by FDA, 20241 |
| Bioavailability | 95% by subcutaneous injection | 170% calculated for oral dosing in pigs, which FDA calls unrealistic; “the magnitude of the oral bioavailability of AOD-9604 remains unclear” | Moré and Kenley, 2014, as summarised by FDA, 20241 |
| Route | Subcutaneous | No human exposure by subcutaneous or transdermal routes identified in FDA's search | FDA, 20241 |
Values from the Milligram app's model.
- Half-life
- ~30 min
- Bioavailability
- 95%
- Typical dose
- 300 mcg/day
- Route
- SubQ
- Time to peak
- ~15 min
The chart below is an illustrative curve drawn from the app's half-life and time to peak. FDA identified no human pharmacokinetic studies, and the trials used intravenous or oral dosing in µg/kg or mg, not this subcutaneous model dose.1,2 The daily interval is the one used in the oral multiple-dose trials of Stier and colleagues.2
Level over 5 days
Level, as a share of the peak after one 300 mcg dose
As studied: every day2.
An illustration from a pharmacokinetic model using a half-life of 0.5 hours. It is not a measured level or a suggested dose.
Human studies
Stier and colleagues summarised six randomized, double-blind, placebo-controlled trials run between 2001 and 2006, with 893 participants, almost all clinically obese adults. Metabolic Pharmaceuticals funded all six.2
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| METAOD001, 20012 | Phase I, double-blind, placebo-controlled dose escalation, recombinant hGH as positive control | 15 healthy adult males, BMI 24 to 30 kg/m² | 25 to 400 µg/kg intravenous, single doses over 20 minutes, 7 days apart | 29 adverse events in 12 subjects, headache most common (6); no serious events; no significant glycerol, glucose or IGF-1 trends |
| METAOD002, 20012 | Phase IIa, double-blind, placebo-controlled, 4 x 4 Latin square | 23 obese males, BMI 36 to 67 kg/m², aged 19 to 50 | 25, 50 or 100 µg/kg intravenous or placebo, single doses 7 days apart | 118 adverse events, none serious; headache in 16 of 23; three severe events (one feeling of chest tightness on 50 µg/kg AOD-9604, deemed possibly related, and two on placebo); mild or moderate euphoria in 5 of 23 while on AOD-9604, none on placebo, deemed possibly related; weight loss over 3 weeks of 0.58 kg on average, not different from placebo, in a 2004 summary by Wilding, as described by FDA1 |
| METAOD003, 20022 | Phase IIa, double-blind, placebo-controlled, 4 x 4 Latin square | 17 obese males, BMI 35 to 56 kg/m², aged 35 to 54; 15 completed | 9, 27 or 54 mg by mouth, single doses 2 weeks apart | 97 adverse events in 17 of 17; two serious events at 54 mg (diarrhoea deemed possibly related, bronchial pneumonia unrelated); no significant IGF-1 change; no significant weight loss against placebo in a 2004 summary by Wilding, as described by FDA1 |
| METAOD004, 20032 | Phase IIa, randomized, double-blind, placebo-controlled dose escalation | 36 obese males, BMI 30 to 47 kg/m², aged 18 to 54; 9 per group | 9, 27 or 54 mg by mouth daily or placebo, 7 days | 207 adverse events in 36 of 36, all but one of mild to moderate intensity; more headaches, diarrhoea and flatulence at 54 mg; IGF-1 constant, fasting glucose and insulin unchanged; in a 2004 summary by Wilding, as described by FDA, average weight loss over 1 week was 1 kg at 10 mg against 0.6 kg on placebo, and the other doses appeared less effective1 |
| METAOD005, 20042 | Phase IIb, randomized, double-blind, placebo-controlled, 5 Australian hospitals | 300 obese adults, BMI 35 or more, aged 30 to 65, 54% male; 50 per group | 1, 5, 10, 20 or 30 mg by mouth daily or placebo, 12 weeks after a 2-week placebo run-in | 88.9% had at least one adverse event; five serious events, all judged unrelated by the investigator (breast cancer, melanoma, basal cell and squamous cell carcinoma, lipoma); no significant IGF-1 change; no antibodies detected |
| METAOD006 (OPTIONS), reported 20071,2 | Phase IIb, randomized, double-blind, placebo-controlled, 16 Australian sites | 502 randomized obese adults, BMI 30 to 45, aged 18 to 65 (536 enrolled per the company filing, 534 per Stier) | 0.25, 0.5 or 1 mg tablets by mouth daily or placebo, 24 weeks after a 4-week run-in | No significant weight-loss difference from placebo at the primary endpoint; 78.7% had at least one adverse event; 18 (3.6%) had serious events: placebo 8, 0.25 mg 3, 0.5 mg 1, 1 mg 6 |
FDA notes that Wilding’s 2004 summary of METAOD002 to METAOD004 rests on company press releases that are no longer available, and lists small sample size, unclear study parameters and limited numerical information among the limitations of those studies.1
Deeper analysis: the 2013 safety summary
Stier, Vos and Kenley (Journal of Endocrinology and Metabolism, 2013) summarised the safety results of the six trials, with special attention to IGF-1, glucose handling and antibodies against the peptide.2 Their conclusion: “AOD9604 displayed a very good safety and tolerability profile indistinguishable from placebo.” They reported no effect on serum IGF-1, no negative effect on carbohydrate metabolism in the oral glucose tolerance tests, no antibodies in the patients selected for antibody assay, and no withdrawal or serious adverse event related to AOD9604 in any of the studies.
The paper lists its own interests: the work was funded by Metabolic Pharmaceuticals; David Kenley “holds a 6.9% interest in Calzada Ltd, which fully owns Metabolic Pharmaceuticals”; Evert Vos is a consultant to the company and was its medical director responsible for the trials; and Heike Stier, who wrote the manuscript, works for a firm that consults to the company on possible novel food applications in Europe.2
The same paper lists a serious diarrhoea event deemed possibly related to 54 mg in the single-dose oral trial, and five serious events in the 12-week trial, three of them skin tumours. The authors argued that none occurred at the highest dose, that Australia has a high skin cancer rate and that cancer incidence rises with BMI. FDA wrote: “We have concerns about the reports of various cancers reported with the 12-week study of oral AOD-9604 administration; information is insufficient whether these various types of cancers were unrelated to AOD-9604.” FDA also noted that the summaries lack detailed adverse-event breakdowns and laboratory values, and that the paper “did not report data on effectiveness”.1
Deeper analysis: weight loss in the 12-week and 24-week trials
FDA's 2024 document describes efficacy results for the 12-week trial (METAOD005) from a 2005 meeting summary by Herd and colleagues, who concluded that daily oral administration “is safe and well tolerated and promotes weight and waistline reduction”. It reported weekly weight loss of 0.22 kg at 1 mg, 0.13 kg at 20 mg and 0.15 kg at 30 mg, against 0.07 kg on placebo, with no details given for the 5 mg and 10 mg groups. The largest effect occurred at 1 mg and was described as “significant” for females. The reduction in waist circumference was statistically significant at all doses. FDA judged that the claim of weight reduction “is based on small differences between the treatment and placebo groups which has unclear meaningful therapeutic effects”, and that it did not locate a publication of the methods and results.1 Stier and colleagues’ acknowledgments name Caroline Herd as the clinical director overseeing the human trials, which Metabolic Pharmaceuticals funded.2
The 24-week trial (METAOD006, called OPTIONS) is known from a company filing to the Australian Stock Exchange, as summarised by FDA. Adults received 0.25, 0.5 or 1 mg by mouth daily or placebo. The primary endpoints were statistically significant weight loss after 12 weeks for any one dose against placebo, and safety.1
The company's statement reads: “Trial results showed that weight loss compared to placebo at the primary and secondary endpoints of 12 or 24 weeks of treatment, was too low to reach statistical significance.” It added that the trial used Phase 3 conditions, including “a formal diet and exercise program”, and that “the overall population did not respond consistently”. FDA states that the study does not appear to have been published in the medical literature, and the 2026 Frontiers review notes that the conclusion of no efficacy rests “primarily on sponsor-reported phase 2 programme outcomes rather than peer-reviewed randomized efficacy trials”.1,3
FDA's overall reading: “In most of the studies we identified, AOD-9604 failed to show benefit when compared to placebo.” Australia's Therapeutic Goods Administration recorded in 2015 that “the obesity program was discontinued in 2007 as the clinical trials did not show a meaningful weight loss outcome across the trial population”, and that AOD-9604 was then being investigated in phase II trials for cartilage repair.1,9
FDA states that its search found no clinical studies of AOD-9604 in osteoporosis or osteoarthritis.1
Doses reported in studies
Reported doses come from the studies below and one review. FDA states that it identified no human exposure by subcutaneous or transdermal routes, and the trial doses below were intravenous or oral, against the app's subcutaneous 300 mcg/day.1
| Setting | Route | Dose reported | Length |
|---|---|---|---|
| Human, METAOD001 and METAOD0022 | Intravenous | 25 to 400 µg/kg and 25 to 100 µg/kg | Single doses |
| Human, METAOD003 and METAOD0042 | Oral | 9, 27 or 54 mg | Single dose; 7 days |
| Human, METAOD0052 | Oral | 1, 5, 10, 20 or 30 mg a day | 12 weeks |
| Human, METAOD0062 | Oral | 0.25, 0.5 or 1 mg a day | 24 weeks |
| Rat6 | Oral | 500 µg/kg a day | 19 days |
| Rabbit7 | Intra-articular | 0.25 mg a week | Weeks 4 to 7 after collagenase |
| Online forums, as summarised in a 2026 review3 | Subcutaneous | 250 to 500 µg/day in 2 to 3 injections; cycles of 8 to 12 weeks | Not a trial |
Side effects reported
In the intravenous trials, adverse events reported as possibly related to AOD-9604 were a feeling of chest tightness (severe intensity) and euphoria (mild to moderate intensity). In the oral trials, headache, diarrhoea and flatulence were the most commonly reported, and more headaches, diarrhoea and flatulence were reported at 54 mg in the 7-day trial.1,2
In the 24-week trial, 78.7% of participants reported at least one adverse event, from 75.6% at 0.25 mg to 83.2% on placebo, and the authors saw no pattern by treatment group. FDA's adverse event database search through 7 January 2024 retrieved no reports for AOD-9604, and FDA states that the lack of reports “does not imply that the substance is safe or lacks toxicities”. A separate FDA web page, current as of 22 April 2026, states that FDA “has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear”.2,1,10
In animals, FDA's evaluation of the nonclinical studies reports “safety signals suggestive of negative effects on bone health” in rats treated orally for 13 weeks, “signals that could be indicative of potential liver toxicity” in cynomolgus monkeys treated orally for 9 months, and “equivocal mutagenic signals” in laboratory and animal genotoxicity assays. In the body of its evaluation, FDA describes a 6-month oral rat study in which serum osteocalcin was significantly lower than in controls at week 13 and significantly higher in females at week 26, and states that these changes “can be interpreted as a clinically relevant nonclinical safety signal”. The article reporting these studies gave no data tables, graphs or statistical analyses, and its authors had concluded that their findings were of no toxicological relevance. FDA concluded that the nonclinical studies “were too limited in scope to inform safety considerations” for the proposed uses.1
On immunogenicity, FDA states that a 16-amino-acid peptide has the potential to be immunogenic, that it found no information on the risk by the subcutaneous or transdermal routes, and that there is “insufficient information to support patient safety for the long-term use” of AOD-9604.1
Bloodwork and markers
Sources in this part
In the 24-week trial, the overall mean change in IGF-1 was 1.76 nmol/L at 12 weeks and 1.24 nmol/L at 24 weeks, with no significant difference between groups (P = 0.50844 and P = 0.75754). Pre-load glucose changed by -0.02 units at 12 weeks (P = 0.73488) and 0.04 at 24 weeks (P = 0.62787), also without significant differences between groups.2
In the 12-week trial, IGF-1 changes from baseline were not significantly different from placebo at any dose, and the oral glucose tolerance test showed a trend toward improved glucose tolerance with no statistically significant change in any measure. All of these data come from sponsor-funded trials.2
A 2013 article from the German Sport University Cologne is titled “AOD-9604 does not influence the WADA hGH isoform immunoassay”; its database record has no summary text, so its methods and results are not described here.11
Regulatory and anti-doping status
| Body | Statement | Reference |
|---|---|---|
| FDA, approval | Not a component of an FDA-approved drug; no USP or NF monograph for the free base or the acetate | FDA, 20241 |
| FDA, compounding | On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 0 yes, 12 no on placing AOD-9604 (free base and acetate) on the 503A bulks list, after FDA proposed that they not be included | FDA minutes, 202412 |
| FDA, safety-risk page | Listed under “Bulk drug substances nominated but withdrawn” (previously in category 2, withdrawn by the nominators), with a statement that compounded AOD-9604 may pose significant immunogenicity risk for certain routes of administration; content current as of 22 April 2026 | FDA web page10 |
| TGA, Australia | Final decision of 19 March 2015: new entries in Schedule 4 and in Appendix D, Item 5 of the Poisons Standard; later amendments are not part of that decision text | TGA, 20159 |
| WADA | Listed among growth hormone fragments in S2 (peptide hormones, growth factors, related substances and mimetics), prohibited at all times; 2026 list in force from 1 January 2026 | WADA, 202613 |
FDA's briefing states its reasoning: “On balance, physicochemical characterization, information on historical use, lack of evidence of effectiveness, and safety information for both AOD-9604 (free base) and AOD-9604 acetate weigh against them being added to the 503A Bulks List.” Among the TGA’s reasons were the limited safety data on intravenous and subcutaneous use and on long-term oral use above trial doses.1,9
In their sponsor-funded paper, Stier and colleagues state that a panel of experts determined AOD9604 to be generally recognized as safe under conditions of intended uses in foods; the paper states no FDA decision.2 Cox and colleagues describe AOD-9604 as “banned by the World Anti-doping Agency”.8
What is not known
- FDA's 2024 evaluation identified no human pharmacokinetic data by any route.1
- FDA's 2024 evaluation describes weight-loss results for the 12-week trial from a meeting summary and for the 24-week trial from a company statement, and states that it did not locate a publication of the 12-week trial's methods and results and that the 24-week trial does not appear to have been published.1
- The mechanism is unconfirmed: FDA states that molecular targets have not been identified.1
- Long-term human safety is not established: FDA states there is insufficient information to support patient safety for long-term use.1
- For cartilage and joint effects, the study cited above is a 2015 rabbit study, and a 2026 review describes a lack of convincing human clinical trial evidence.7,3
Frequently asked questions
What is AOD-9604?
What is the half-life of AOD-9604?
Is AOD-9604 banned by WADA?
Yes: the WADA 2026 Prohibited List names AOD-9604 as an example of growth hormone fragments in class S2, which is prohibited at all times.13
Did AOD-9604 cause weight loss in human trials?
In the 24-week trial of 502 adults, the company reported weight loss against placebo too low to reach statistical significance at the primary and secondary endpoints.1 A 12-week trial of 300 adults was described in a 2005 meeting summary as showing greater weight loss than placebo at all doses, which FDA called small differences of unclear therapeutic meaning.1
Does AOD-9604 raise IGF-1?
Stier and colleagues, reporting sponsor-funded trials, state that AOD9604 had no effect on serum IGF-1 levels; in the 24-week trial the differences between groups were not statistically significant (P = 0.50844 at 12 weeks, P = 0.75754 at 24 weeks).2
Is AOD-9604 approved by the FDA?
What is the Australian status of AOD-9604?
In a final decision dated 19 March 2015, the TGA delegate added AOD-9604 to Schedule 4 and to Appendix D, Item 5 of the Poisons Standard.9
What side effects were reported in AOD-9604 trials?
Headache was the most common adverse event across the trials, and diarrhoea and flatulence were commonly reported in the oral trials, with more at 54 mg; 18 of 502 participants (3.6%) in the 24-week trial had a serious event, including 8 on placebo.2 In the 12-week trial, five serious events were cancers and a lipoma, which the investigator judged unrelated to the study drug, while FDA states that information is insufficient to say whether the cancers were unrelated.2,1 A serious diarrhoea event at 54 mg in the single-dose oral trial was deemed possibly related; chest tightness and euphoria in the intravenous trial were possibly related events, not serious events.1,2
Has AOD-9604 been studied by subcutaneous injection in people?
FDA's 2024 evaluation identified no human exposure to AOD-9604 by the subcutaneous or transdermal route; the human trials it reviewed were intravenous and oral.1
Guides, tools and comparisons
- AOD-9604 dosageA guide that answers a question on this compound.
- Calculator for AOD-9604A calculator set up for this compound.
- Previous in Growth hormone peptides: Tesamorelin + IpamorelinThe compound before this one in the class.
- Next in Growth hormone peptides: CJC-1295 (no DAC)The compound after this one in the class.
References
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: FDA Evaluation of AOD-9604-Related Bulk Drug Substances. 2024. FDA briefing document
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3(1-2):7-15. J Endocrinol Metab 2013
- Dominikowski A, Rekos Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 2001. PMID 11673763
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001. PMID 11713213
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000. PMID 11146367
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci 2015. PMID 26275694
- Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal 2015. PMID 25208511
- Therapeutic Goods Administration. Delegates' final decisions and reasons for decisions, 19 March 2015. TGA final decisions
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). FDA web page
- Orlovius AK, Thomas A, Schanzer W, Thevis M. AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug Test Anal 2013. PMID 24124033
- US Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. 2024. FDA summary minutes
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026